Brilinta DaYu Study
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2004 participants.
Also called NCT01870921
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,004 participants
- Sponsor
- Registry
-
NCT01870921
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT01870921. Allocation not applicable; no masking; primary purpose treatment. Start 2013-06-26 (actual); primary completion 2015-09-30 (actual). Results posted on 2016-11-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Brilinta DaYu Study
- Acronym
- DaYu
- Condition
- Acute Coronary Syndrome
- Intervention (Drug)
- Ticagrelor
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct01870921- Content hash
c0eacab8a8eeb3994a537faa89b5f8b7c9d22fab280b06fd4087268e1d88eba1